Khaled bin Mohamed chairs Emirates Genome Council meeting

Advancing precision medicine and public health
During the meeting, the board discussed plans to prioritise precision medicine initiatives aimed at enhancing public health, improving the efficiency of the healthcare system, driving economic growth, and establishing the UAE as a global leader in genomics. Sheikh Khaled reaffirmed the UAE leadership's commitment to advancing health and wellbeing through research and development in longevity, precision medicine, and preventative care.
New population screening programmes
His Highness Sheikh Khaled endorsed new population screening programmes to accelerate genome-driven personalised healthcare. These programmes include newborn genetic screenings, adult disease screenings, personalised fertility programmes, and cardiovascular genetic screenings. These initiatives aim to identify genetic conditions early and provide personalised treatments for affected individuals.
Updates on key genomic research and initiatives
Sheikh Khaled was briefed on the completion of the Telomere-to-Telomere (T2T) Emirati Reference Genome study, which aims to enhance precision medicine by filling gaps in genomic data. He was also updated on the progress of the Premarital Genetic Screening Programme, launched in January 2025, which supports couples in making informed family planning decisions by identifying genetic compatibility and providing personalised counseling.
Emirati Genome Programme progress
The Emirati Genome Programme has made significant progress, with more than 700,000 genetic samples collected from UAE citizens. Additionally, the program has started collecting samples from other nationalities to address global gaps in genomic data and promote international collaboration in precision medicine research.
Future of healthcare transformation
The Emirati Genome Programme is a critical component of the National Genome Strategy and will play a pivotal role in transforming healthcare services in the UAE. By providing high-quality genetic data, it will help researchers and healthcare providers understand genetic diseases, predict disease susceptibility, and create personalised healthcare plans.
Attendees of the meeting
The meeting was attended by several key officials, including Mohammad Al Gergawi, UAE Minister of Cabinet Affairs; Sarah bint Yousef Al Amiri, UAE Minister of Education; Omar bin Sultan Al Olama, UAE Minister of State for Artificial Intelligence, Digital Economy, and Remote Work Applications; Mansour Ibrahim Al Mansouri, Chairman of the Department of Health – Abu Dhabi; Saif Saeed Ghobash, Secretary General of the Abu Dhabi Executive Council; and other prominent health leaders.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

TECHx

8 hours ago

• TECHx

Abu Dhabi, Abbott Partner to Boost Local Pharma Sector

Home » Smart Sectors » Healthcare » Abu Dhabi, Abbott Partner to Boost Local Pharma Sector The Department of Health, Abu Dhabi (DoH), the healthcare sector regulator in Abu Dhabi, announced a strategic partnership with global healthcare leader Abbott. The agreement was signed during the BIO International Convention held in Boston, USA. The partnership aims to localise pharmaceutical manufacturing in Abu Dhabi. It also focuses on advancing digital health solutions across the emirate. Officials revealed that the collaboration builds on Abu Dhabi's advanced life sciences infrastructure. This move supports the emirate's goal to reduce dependency on imports and strengthen supply chain resilience. It further reflects Abu Dhabi's commitment to fostering a self-sufficient and sustainable healthcare ecosystem. Dr. Noura Al Ghaithi, Undersecretary of DoH, stated that the partnership follows the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi. She added that the emirate is equipped with an integrated infrastructure to support local manufacturing and R&D. She said the agreement would position Abu Dhabi as a regional healthcare hub and leader in life sciences. According to her, aligning DoH's strategic vision with Abbott's global expertise will accelerate the delivery of innovative healthcare products and solutions. The collaboration is built around four key pillars: Localising Abbott's pharmaceutical portfolio and developing biosimilars. Advancing digital transformation through electronic patient information leaflets. Launching education programs to strengthen the healthcare workforce. Supporting regulatory alignment and joint R&D initiatives. Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, reported that this partnership will enhance healthcare resilience and innovation in Abu Dhabi. He highlighted Abbott's ongoing commitment to the UAE's healthcare system. He noted that the partnership will also include digitising life sciences product information and launching training initiatives to build local capabilities. In addition, both parties will explore opportunities for joint research and development. DoH also reported that a high-level delegation has embarked on a strategic mission to the United States from 15 to 21 June 2025. The delegation will conduct over 20 meetings with public and private sector leaders. These meetings aim to promote knowledge exchange, attract investments, and sign new agreements that accelerate advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes: Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, and PureHealth. Etihad Cargo, New York University Abu Dhabi, Khalifa University, startAD, and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). This announcement highlights Abu Dhabi's global ambitions in life sciences and healthcare innovation.

Filipino Times

11 hours ago

• Filipino Times

Abu Dhabi launches personalized weight loss programme; first in the Middle East

Abu Dhabi has launched the region's first Personalised Weight Management Programme to help residents manage their weight and prevent serious health problems. The program aims to lower the risk of diseases like type 2 diabetes, heart problems, and some cancers, improving the quality of life and helping people live longer, Abu Dhabi Media Office reported. An initiative of the Department of Health – Abu Dhabi (DoH) and Abu Dhabi Public Health Centre (ADPHC), this is the first program of its kind in the Middle East that combines online health tracking, insurance support, and medical care tailored to each person. 'Our focus is on health – not just weight. This programme supports our vision for an active, health-conscious community, empowering individuals through personalised and science-driven solutions,' Dr. Noura Al Ghaithi, Undersecretary of DoH, said. Those eligible include Thiqa insurance members aged 18 and above who are medically classified as overweight or obese. The plan includes early health checks, one-on-one coaching, diet and exercise guidance, and check-ups using the Sahatna health app.

Al Etihad

a day ago

• Al Etihad

DoH, Abbott unite to manufacture pharmaceuticals locally in Abu Dhabi

20 June 2025 22:37 BOSTON (WAM) Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Abbott, the global healthcare leader, entered a landmark partnership during the BIO International Convention in Boston agreement aims to localise the manufacturing of pharmaceuticals in Abu Dhabi and advance digital health Abu Dhabi's advanced life sciences infrastructure, this milestone reflects the emirate's proactive preparedness to reduce dependency on imports, strengthen supply chain resilience, and foster a sustainable, self-sufficient healthcare Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi, said, 'Following the recent launch of the Health, Endurance, Longevity and Medicine (HELM) Cluster in Abu Dhabi, the emirate proved to be equipped with a holistic, integrated infrastructure that fosters local manufacturing and R&D, positioning it as a regional healthcare gateway and leader in life sciences." She added, "By integrating our strategic vision with Abbott's expertise, we aim to accelerate the development and deployment of innovative healthcare products and solutions, reducing time-to-market, improving healthcare outcomes, and ensuring that breakthrough therapies reach patients faster. This approach positions Abu Dhabi as a regional leader in fostering an agile, innovation-driven healthcare ecosystem that directly translates scientific advancements into tangible benefits for our community.'The strategic collaboration outlines a comprehensive plan focusing on four key pillars including localisation of Abbott's pharmaceutical portfolio, biosimilar development, digital transformation through electronic patient information leaflets, and a robust education and workforce development his part, Mazen Bachir, Regional Director for Abbott's established pharmaceuticals business in the Gulf, Emerging Markets and Levant, said, 'Abbott is proud to announce a strategic collaboration with the Department of Health – Abu Dhabi, aimed at advancing healthcare resilience and innovation in Abu Dhabi." Bachir added, "Building on Abbott's long-standing commitment to the UAE's healthcare system, this partnership will focus on localising existing pharmaceutical products, and jointly exploring the development of biosimilars, supported by regulatory alignment. The collaboration also includes initiatives to digitise life science product information through electronic leaflets in alignment with the UAE's digital health strategy. Another key component of this collaboration is the development of education programs to build local capabilities. Additionally, Abbott and the Department of Health will evaluate opportunities for joint research and development to strengthen long-term healthcare sustainability in the UAE.'Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 15 - 21, 2025. The delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the US, aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI).